Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWoodbois Regulatory News (WBI)

  • This share is currently suspended. It was suspended at a price of 0.03
  • There is currently no data for WBI

Board Changes

23 Mar 2017 07:00

RNS Number : 2694A
Obtala Limited
23 March 2017
 

23 Mar 2017

Obtala Limited

("Obtala", the "Group" or the "Company")

(AIM: OBT)

 

 

Board Changes

 

 

Obtala Limited (AIM: OBT), the African focused agricultural and forestry company, is pleased to announce the appointment of Ms. Jessica Camus to the Board in the role of Non-executive Director with immediate effect.

 

Jessica brings extensive experience facilitating public private partnerships working with leaders from private sector, government and civil society globally, and across Sub-Saharan Africa. Jessica, aged 33, specialises in accelerating growth and impact for socially responsible business in frontier markets. Previously an Associate Director at the World Economic Forum, developing numerous initiatives and programmes on building entrepreneurship ecosystems, innovation and gender. Former Financial Market Executive at Thomson Reuters; Jessica has held various assignments in international organizations. Jessica holds an MA from the Graduate Institute of International Relations & Development Studies, Geneva and an MBA from the IE Business School, Madrid.

 

Jessica's primary responsibilities will be the Company's strategic engagement with multilateral organizations, civil society and key funding partners of socially impactful programmes in Africa.

 

Miles Pelham, Chairman of Obtala, commented "I am delighted to welcome Jessica to the Board of Obtala and look forward to her contribution and guidance with regard to our social impact responsibilities.

 

"Jessica joins Obtala at a time of rapid expansion and it is of the utmost importance that the pace of this expansion does not leave behind our strong commitment to ethical standards. Jessica will immediately help by devising programmes that economically empower local communities and making sure that impact measurement is an integral part of our reporting processes.

 

"All stakeholders should welcome Jessica's appointment which will amplify Obtala's social impact efforts. The policies, programmes and processes to be implemented

will aim to contribute to profound positive change in the communities in which we operate."

 

 

Obtala Limited

Miles Pelham - ChairmanPaul Dolan - CEO

www.obtala.com

 

+44 (0)20 7099 1940

ZAI Corporate Finance Limited (Nomad)  

Peter Trevelyan-Clark / John Treacy

 

+44 (0)20 7060 2220

Brandon Hill Capital (Broker)  

Jonathan Evans

 

+44 (0)20 3463 5000

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Other Information 

 

Directorships and partnerships currently held or previously held in the last five years by Jessica Camus are as follows:

 

Current: Ignis Consulting Sarl, Partner and Managing Director since June 2016

 

Ms. Camus (full name Adele Jessica Cynthia Engie Camus-Demarche, née Dyllick-Brenzinger) holds no shares in Obtala Limited or in any Obtala group company.

 

There are no further disclosures to be made pursuant to Schedule 2(g) or Rule 17 of the AIM Rules for Companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAZMGZFVFNGNZG
Date   Source Headline
27th Jun 20247:00 amRNSAppointment of Independent Non-Executive Director
24th Jun 20247:00 amRNS$5m Trade Finance Facility Completed
12th Jun 20247:00 amRNSBoard Changes & Trading Update
10th Jun 20247:00 amRNSUpdate on Publication of Financial Statements
23rd May 20241:43 pmRNSHolding(s) in Company
13th Mar 20247:00 amRNSMozambique Operations to be Divested
8th Feb 20247:05 amRNS£2.0m Exercise of Warrants to scale-up production
8th Feb 20247:00 amRNS$5m Trade Finance, Gabon Progress & 2024 Outlook
12th Jan 20247:00 amRNSIssuance of Shares and Warrants
5th Jan 20247:00 amRNSCEO Departure Commences Restructuring
29th Dec 202312:27 pmRNSResults of Annual General Meeting
29th Dec 20237:00 amRNSBoard Change, Strategic Initiatives & Joint Broker
4th Dec 20237:00 amRNSDirectorate Change
22nd Nov 20237:00 amRNSNotice of Annual General Meeting
29th Sep 20237:00 amRNSHalf Year Results
30th Aug 20239:05 amRNSStatement re Share Price Movement
29th Jun 20231:30 pmRNSDirector/PDMR Shareholding
28th Jun 20237:00 amRNSSubscription, Debt Refinancing & Issue of Warrants
16th Jun 202312:00 pmRNSResults of General Meeting
9th Jun 20237:00 amRNSAudited results for FY 2022
6th Jun 20237:00 amRNSDebt Repayment Terms and Corporate Update
30th May 20237:00 amRNSNotice of General Meeting and Posting of Circular
19th Apr 202311:45 amRNSTR-1
19th Apr 20237:14 amRNSFacility with Sydbank A/S ("Sydbank")
11th Apr 20237:01 amRNSQ1 2023 Update
11th Apr 20237:00 amRNSConditional Award of Afforestation Project
13th Mar 20237:00 amRNSPlacing of £3 million
10th Mar 20231:00 pmRNSTR-1
10th Mar 202312:41 pmRNSResponse to market speculation
2nd Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 202310:40 amRNSTR-1
24th Feb 202311:15 amRNSTR-1
31st Jan 20231:45 pmRNSTR-1
12th Jan 20237:00 amRNSQ4 2022 update
5th Dec 20225:30 pmRNSTR-1
11th Nov 20227:00 amRNSConversion of 55 million Non-Voting Shares
1st Nov 20228:15 amRNSTR-1
27th Oct 20225:15 pmRNSConversion of 60 million Non-Voting Shares
21st Oct 20227:00 amRNSTR-1
17th Oct 20227:00 amRNSQ3 2022 Upate an Boar change
17th Oct 20227:00 amRNSQ3 2022 Update and Board change
26th Sep 20224:15 pmRNSTR-1
26th Sep 20227:00 amRNSConversion of 60 million Non-Voting Shares
17th Aug 20227:00 amRNSEighth Ranking in SPOTT Transparency Assessment
10th Aug 20229:00 amRNSExercise of Options
4th Aug 20227:00 amRNSHalf Year Results
11th Jul 20227:00 amRNSQ2 2022 update
27th Jun 20227:00 amRNSConversion of 65 million Non-Voting Shares
16th Jun 20227:00 amRNSConversion of $243,591 of Convertible Bonds
14th Jun 20227:00 amRNSConversion of $50,000 of Convertible Bonds

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.